These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716 [TBL] [Abstract][Full Text] [Related]
7. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804 [TBL] [Abstract][Full Text] [Related]
8. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model. Weiss KR; Kimura Y; Lee WC; Littleton JT Genetics; 2012 Feb; 190(2):581-600. PubMed ID: 22095086 [TBL] [Abstract][Full Text] [Related]
9. Evidence for a recruitment and sequestration mechanism in Huntington's disease. Preisinger E; Jordan BM; Kazantsev A; Housman D Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302 [TBL] [Abstract][Full Text] [Related]
13. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract. Hazeki N; Nakamura K; Goto J; Kanazawa I Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189 [TBL] [Abstract][Full Text] [Related]
14. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro. Ermak G; Hench KJ; Chang KT; Sachdev S; Davies KJ J Biol Chem; 2009 May; 284(18):11845-53. PubMed ID: 19270310 [TBL] [Abstract][Full Text] [Related]
15. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease. Alberch J; López M; Badenas C; Carrasco JL; Milà M; Muñoz E; Canals JM Neurology; 2005 Sep; 65(6):964-5. PubMed ID: 16186551 [No Abstract] [Full Text] [Related]
16. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Dyer RB; McMurray CT Nat Genet; 2001 Nov; 29(3):270-8. PubMed ID: 11600884 [TBL] [Abstract][Full Text] [Related]
17. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753 [TBL] [Abstract][Full Text] [Related]
18. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620 [TBL] [Abstract][Full Text] [Related]
19. An intriguing new lead on Huntington's disease. Barinaga M Science; 1996 Mar; 271(5253):1233-4. PubMed ID: 8638101 [No Abstract] [Full Text] [Related]
20. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]